Friday, April 08, 2022 12:10:33 AM
Stock down over 50 percent YTD and this kind of posting over a .02 cent rise in price is comical. Company has done nothing but miss deadlines and fail to deliver and the 63 percent decline in price over the last 6 months shows that’s how the market feels. Trial has been going since August 7 2020 and still not up to 800 patients enrolled during a pandemic is FAILURE.
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
